c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Cancer Research

• Publication date

  2007-02-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-1147PMID 17308108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• COX‐2 inhibitors suppress integrin α5 expression in human lung carcinoma cells through activation of Erk: Involvement of Sp1 and AP‐1 sites

  2005cited by this paper
• Regulation of α5β1 integrin conformation and function by urokinase receptor binding

  2005cited by this paper
• Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor

  2005cited by this paper
• Proliferation and invasion: plasticity in tumor cells.

  2005cited by this paper
• C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

  2005cited by this paper
• Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer.

  2005cited by this paper
• Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation.

  2004cited by this paper
• RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival

  2004cited by this paper
• Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

  2003cited by this paper
• Helicobacter pylori CagA protein targets the c-Met receptor and enhances the motogenic response

  2003cited by this paper
• Met, metastasis, motility and more

  2003cited by this paper
• Tissue microarray‐based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors

  2003cited by this paper
• The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.

  2003cited by this paper
• Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.

  2003cited by this paper
• Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.

  2002cited by this paper
• Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis

  2002cited by this paper
• Neuregulin expression, function, and signaling in human ovarian cancer cells.

  2002cited by this paper
• Biological significance of c-met over expression in papillary renal cell carcinoma.

  2002cited by this paper
• Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma.

  2001cited by this paper
• Ovarian surface epithelium: biology, endocrinology, and pathology.

  2001cited by this paper
• Human &-Integrin Gene Expression Is Regulated by Two Promoter Regions *

  2001cited by this paper
• Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?

  2001cited by this paper
• Pathway specificity for Met signalling

  2001cited by this paper
• Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival

  2001cited by this paper
• Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.

  2001cited by this paper
• Ras regulation of urokinase-type plasminogen activator.

  2001cited by this paper
• Mesothelial cells induce the motility of human ovarian carcinoma cells

  1999cited by this paper
• CD44 and beta1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells.

  1999cited by this paper
• CD44 and β1 Integrin Mediate Ovarian Carcinoma Cell Adhesion to Peritoneal Mesothelial Cells

  1999influential reference
• Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor*

  1999cited by this paper
• Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro.

  1999influential reference
• Metastatic Dissemination of Human Ovarian Epithelial Carcinoma Is Promoted by α2β1-Integrin-Mediated Interaction with Type I Collagen

  1999cited by this paper
• Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor

  1998cited by this paper
• Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen.

  1998cited by this paper
• Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c‐MET

  1997cited by this paper
• The AP-1 site and MMP gene regulation: what is all the fuss about?

  1997cited by this paper
• Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin.

  1996cited by this paper
• Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the αA2β1 integrin

  1996cited by this paper
• Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene.

  1995cited by this paper
• Overexpression of the MET/HGF receptor in ovarian cancer

  1994cited by this paper
• Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript.

  1994cited by this paper
• Cancer of the ovary.

  1993cited by this paper
• Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.

  1993influential reference
• Human beta 1-integrin gene expression is regulated by two promoter regions.

  1993cited by this paper
• The alpha 5 beta 1 fibronectin receptor. Characterization of the alpha 5 gene promoter.

  1991cited by this paper
• Isolation, culture and characterization of human peritoneal mesothelial cells.

  1990cited by this paper
• Mesothelial cells stimulate the anchorage-independent growth of human ovarian tumour cells.

  1989cited by this paper
• The FASEB Journal express article 10.1096/fj.01-0421fje. Published online November 29, 2001.

  year unknowncited by this paper

• MEN1-Related Neuroendocrine Tumors Show c-MET Overexpression.

  2025cites this paper
• Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression.

  2025cites this paper
• The chemotherapy-induced senescence-associated secretome promotes cell detachment and metastatic dissemination through metabolic reprogramming

  2025cites this paper
• Small molecule MET kinase inhibitors: Evolution, rational design, and early clinical knowledge.

  2025cites this paper
• Advances in pharmacotherapy for the treatment of peritoneal metastases from colorectal cancer

  2024cites this paper
• Overcoming Chemoresistance in Cancer: The Promise of Crizotinib

  2024cites this paper
• Methods for assessing and removing non‐specific photoimmunotherapy damage in patient‐derived tumor cell culture models

  2024cites this paper
• Patient-Derived Exosomes as siRNA Carriers in Ovarian Cancer Treatment

  2024cites this paper
• Loss of LECT2 promotes ovarian cancer progression by inducing cancer invasiveness and facilitating an immunosuppressive environment

  2024cites this paper
• Epinephrine, Pregabalin, and Crizotinib as Three Medicines with Polish Implications over Three Last Centuries and in View of Three Different Drug Discovery Approaches

  2024cites this paper
• Progress of antibody–drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies

  2024cites this paper
• Antibody-drug conjugates in lung cancer: dawn of a new era?

  2023cites this paper
• Exploring the tumor immune microenvironment in ovarian cancer: a way-out to the therapeutic roadmap

  2023cites this paper
• Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression

  2023cites this paper
• HGF/C-Met Expression in Epithelial Ovarian Carcinogenesis and Its Potential as Molecular Targeted Therapy

  2023cites this paper
• Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies

  2023cites this paper
• Scutellaria baicalensis Georgi and Their Natural Flavonoid Compounds in the Treatment of Ovarian Cancer: A Review

  2023cites this paper
• Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine

  2023cites this paper
• c-Met+ Cytotoxic T Lymphocytes Exhibit Enhanced Cytotoxicity in Mice and Humans In Vitro Tumor Models

  2023cites this paper
• Prognostic utility of the ovarian cancer secretome: a systematic investigation

  2022cites this paper
• c-Met-integrin cooperation: Mechanisms, tumorigenic effects, and therapeutic relevance

  2022cites this paper
• Ascitic fluid shear stress in concert with hepatocyte growth factor drive stemness and chemoresistance of ovarian cancer cells via the c-Met-PI3K/Akt-miR-199a-3p signaling pathway

  2022cites this paper
• Combined Expression of HGFR with Her2/neu, EGFR, IGF1R, Mucin-1 and Integrin α2β1 Is Associated with Aggressive Epithelial Ovarian Cancer

  2022cites this paper
• Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase

  2022cites this paper
• High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas

  2022cites this paper
• Tumor vessel co-option: The past & the future

  2022cites this paper
• Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting

  2022cites this paper
• Zirkulierendes HGF als prognostischer Biomarker bei Patientinnen mit Ovarialkarzinom

  2021cites this paper
• Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

  2021cites this paper
• Investigation of β5 integrin function in epithelial ovarian cancer cell adhesion and metastatic properties of spheroids

  2021cites this paper
• Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer

  2021cites this paper
• Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer

  2021cites this paper
• MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian Cancer

  2021cites this paper
• Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition

  2021cites this paper
• Computational study on novel natural inhibitors targeting c-MET

  2021cites this paper
• The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker

  2021cites this paper
• Molecular and cellular mechanisms controlling integrin-mediated cell adhesion and tumor progression in ovarian cancer metastasis: a review

  2021cites this paper
• Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.

  2021cites this paper
• Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors

  2021cites this paper
• Ovulation sources coagulation protease cascade and hepatocyte growth factor to support physiological growth and malignant transformation

  2021cites this paper
• Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type

  2020cites this paper
• Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma

  2020cites this paper
• Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy

  2020cites this paper
• FER-mediated tyrosine phosphorylation and PIK3R2/p85β recruitment on IRS4 promotes the PI3K-AKT signaling pathway and tumorigenesis in ovarian cancer

  2020influential citation
• Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?

  2020cites this paper
• Molecular mediators of peritoneal metastasis in pancreatic cancer

  2020cites this paper
• Recurrence of ovarian squamous cell carcinoma with MET gene copy number variation: a case report and review of literature

  2020cites this paper
• A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance

  2020cites this paper
• A Potential Mechanism of Tumor Progression during Systemic Infections Via the Hepatocyte Growth Factor (HGF)/c-Met Signaling Pathway

  2020cites this paper
• Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma

  2019cites this paper
• Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer

  2019cites this paper
• Correlation of long interspersed element-1 open reading frame 1 and c-Met proto-oncogene protein expression in ovarian cancer

  2019cites this paper
• Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.

  2019cites this paper
• Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.

  2019cites this paper
• 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 2

  2019cites this paper
• Recent Progress in the Development of Small Molecule c-Met Inhibitors.

  2019cites this paper
• Clinical significance of c-Met and phospho-c-Met (Tyr1234/1235) in ovarian cancer.

  2019cites this paper
• Therapeutic Inducers of Apoptosis in Ovarian Cancer

  2019cites this paper
• MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population

  2019cites this paper
• Sialyl Lewisx-P-selectin cascade mediates tumor–mesothelial adhesion in ascitic fluid shear flow

  2019cites this paper
• Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma

  2019cites this paper
• Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer

  2018cites this paper
• Spatial regulation of signaling by the coordinated action of the protein tyrosine kinases MET and FER.

  2018cites this paper
• Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis

  2018influential citation
• The HGF/MET Signaling and Therapeutics in Cancer

  2018cites this paper
• Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis.

  2018cites this paper
• First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

  2018cites this paper
• Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.

  2018cites this paper
• The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo.

  2017cites this paper
• Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer

  2017cites this paper
• CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells

  2017cites this paper
• MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection

  2017cites this paper
• Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.

  2017cites this paper
• MicroRNA-1 inhibits ovarian cancer cell proliferation and migration through c-Met pathway.

  2017cites this paper
• PD-L1 and c-MET expression and survival in patients with small cell lung cancer

  2017cites this paper
• Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells

  2017cites this paper
• Crizotinib synergizes with cisplatin in preclinical models of ovarian cancer.

  2017cites this paper
• Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer

  2017cites this paper
• The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance (Review).

  2017cites this paper
• Cancer stem cells and homologous recombination deficiency in serous ovarian and endometrial carcinoma

  2017cites this paper
• 6-Gingerol is the most Potent Anticancerous Compound in Ginger (Zingiber officinale Rosc.)

  2017cites this paper
• Mining the forest: uncovering biological mechanisms by interpreting Random Forests

  2017cites this paper
• The Antitumor Effect of C-terminus of Hsp70-Interacting Protein via Degradation of c-Met in Small Cell Lung Cancer

  2017cites this paper
• Notch3 Signaling Promotes Adhesion and Tumor Progression in a Murine Epithelial Ovarian Cancer Model

  2017cites this paper
• A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.

  2017cites this paper
• c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients.

  2016influential citation
• Comparative study between serum level of hepatocyte growth factor and CA-125 in patients with suspicious malignant adnexal masses

  2016cites this paper
• Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET.

  2016cites this paper
• MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker

  2016cites this paper
• Monitoring of ovarian cancer cell invasion in real time with frequency-dependent impedance measurement.

  2016cites this paper
• miR-17 inhibits ovarian cancer cell peritoneal metastasis by targeting ITGA5 and ITGB1.

  2016cites this paper
• Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models

  2016cites this paper
• HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer

  2016cites this paper
• A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models

  2016cites this paper
• Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis

  2016cites this paper
• Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

  2016cites this paper
• Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells

  2016cites this paper
• Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells

  2016cites this paper
• Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.

  2016cites this paper
• Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance

  2016cites this paper